
Company Spotlight
MTTI Builds an Albumin-Binding Radiopharmaceutical Platform
MTTI is building EvaThera, an albumin-binding radiopharmaceutical platform spanning neuroendocrine tumors, lung cancer, thyroid cancer, and imaging tools.
Jesse Landry
In-depth spotlights on standout Radiopharmaceutical Biotechnology startups and tech companies.